MedDataX Logo

Surgery for Intravenous Leiomyomatosis

NCT ID: NCT01707862

Last Updated: 2012-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

1997-03-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intravenous leiomyomatosis (IVL) with intracardiac extension is a rare benign smooth muscle tumor. Reviewing literature, intracardiac extension of the IVL has been reported in at least 70 cases. Most are individual case reports. Surgical experience is not much. However, different opinion of surgical strategies remain controversial. The purpose of this report is to describe our experience of surgical management for the IVL with intracardiac extension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients underwent surgical management. Clinical data were obtained from medical reports. Following-up was made through email and telephone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leiomyomatosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Intravenous leiomyomatosis Surgery Smooth muscle tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age more than 18 years.
* Tumor markers were all within normal limits.
* Patients underwent surgical management.
* Patients were followed-up for more than 12 months.

Exclusion Criteria

-Tumor markers were all within abnormal limits
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Li Yang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Li Yang

Doctor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Genetal Hospital Beijing Military Region, First class

Role: PRINCIPAL_INVESTIGATOR

Institute of Cardiovascular Disease

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Cardiovascular Disease

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GHBeijing-20121012

Identifier Type: -

Identifier Source: org_study_id